JAMA cardiology最新文献

{"title":"Error in Author Surname.","authors":"","doi":"10.1001/jamacardio.2026.1448","DOIUrl":"10.1001/jamacardio.2026.1448","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":" ","pages":""},"PeriodicalIF":14.1,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13130055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147771728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiplatelet Therapy After CABG-Toward a Mechanistic Approach.","authors":"Sigrid Sandner,Raffaele De Caterina,Mario Gaudino","doi":"10.1001/jamacardio.2026.0840","DOIUrl":"https://doi.org/10.1001/jamacardio.2026.0840","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"31 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147731297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"US Trends in Prescribing Nonstatin Lipid-Lowering Therapy, 2019-2024.","authors":"Semenawit Burka,Omar Dzaye,Tianyu Cao,John Erhabor,Yara Jelwan,Khurram Nasir,Maciej Banach,Michael J Blaha","doi":"10.1001/jamacardio.2026.0844","DOIUrl":"https://doi.org/10.1001/jamacardio.2026.0844","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"21 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147731300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Rule Out of Myocardial Infarction With a Novel High-Sensitivity Cardiac Troponin T Assay.","authors":"Alexander J F Thurston,Yong Yong Tew,Pedro Lopez-Ayala,Luca Koechlin,Rachel O'Brien,Stephen Lynch,Jamie G Cooper,Takeshi Fujisawa,Paolo Bima,Michael McDermott,Chris Tuck,Mizu Mizerska,Elizabeth Highton-Williamson,Fiona McCurrach,Matthew T H Lowry,Dimitrios Doudesis,Atul Anand,Kuan Ken Lee,Amy V Ferry,Andrew Chapman,David E Newby,Jasper Boeddinghaus,Christian Mueller,Alasdair J Gray,Nicholas L Mills, ","doi":"10.1001/jamacardio.2026.0477","DOIUrl":"https://doi.org/10.1001/jamacardio.2026.0477","url":null,"abstract":"ImportanceIn the emergency department, patients at low risk of myocardial infarction can be identified at presentation using a single cardiac troponin measurement with high-sensitivity assay.ObjectivesTo define a threshold to identify patients at low risk of myocardial infarction for the sixth-generation high-sensitivity cardiac troponin T (hs-cTnT) assay and to evaluate the impact of applying this in an early rule-out pathway.Design, Setting, and ParticipantsThis was a prospective multicenter cohort study conducted from 2022 to 2025 (derivation cohort) and 2014 to 2019 (validation cohort). The setting included emergency departments at hospitals in Scotland (derivation cohort) and Czechia, Italy, Poland, Spain, and Switzerland (validation cohort). Participants included adults with possible non-ST-segment elevation myocardial infarction (both cohorts). Study data were analyzed from May to October 2025.ExposuresCardiac troponin concentration measured at presentation and on serial samples using fifth-generation and novel sixth-generation hs-cTnT assays.Main Outcomes and MeasuresOutcomes included the highest threshold at presentation with negative predictive value (NPV) greater than or equal to 99.5% and sensitivity greater than or equal to 99% for an adjudicated primary outcome of type 1, 4b, or 4c myocardial infarction or cardiac death at 30 days. Performance of an early rule-out pathway with the sixth-generation assay.ResultsIn total, 987 patients (median [IQR] age, 59 [50-70] years; 611 male [62%]) were recruited, with 82 (8.3%) meeting the primary outcome. At presentation, 601 patients (61%) had a cardiac troponin T concentration less than 13 ng/L using the sixth-generation hs-cTnT assay, with an NPV of 99.9% (95% credible interval [CrI], 99.7%-100%) and sensitivity of 99.4% (95% CrI, 97.7%-100%). More patients were identified as low risk at presentation in the early rule-out pathway when using the sixth-generation assay compared with fifth-generation assay (376 [41.0%] vs 160 [17.4%]; P < .001). In the external validation cohort, 782 of 1721 patients (45.4%) had a sixth-generation hs-cTnT measurement less than 13 ng/L at presentation with an NPV of 99.0% (95% Cr, 98.3%-99.6%) and sensitivity of 97.5% (95% Cr, 95.8%-99.0%), compared with 118 (6.9%) below the low risk-stratification threshold of the fifth-generation hs-cTnT assay (P < .001).Conclusions and RelevanceResults of this cohort study suggest that compared with the fifth-generation hs-cTnT assay, use of the sixth-generation assay with a risk-stratification threshold based on clinical performance could double identification of patients at low risk of myocardial infarction or cardiac death at presentation. Prospective studies are required to evaluate the impact of implementation on practice.","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"21 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147731298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Rule Out With a Refreshed Troponin Assay.","authors":"John W Pickering","doi":"10.1001/jamacardio.2026.0469","DOIUrl":"https://doi.org/10.1001/jamacardio.2026.0469","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"263 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147731299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial Fibrosis and Early Intervention in Asymptomatic Patients With Severe Aortic Stenosis: Insights From the EVOLVED Randomized Clinical Trial.","authors":"Neil J Craig,Krithika Loganath,Russell J Everett,Rong Bing,Tariq Ramtoola,Vasiliki Tsampasian,Patrycja Molek,Simona Botezatu,Saadia Aslam,Tom MacGillivray,Christopher E Tuck,Phillip Rayson,Patrick A Calvert,Colin Berry,Calvin W L Chin,Graham S Hillis,Timothy Fairbairn,John P Greenwood,Richard Steeds,Stephen J Leslie,Chim C Lang,Chiara Bucciarelli-Ducci,Nikhil V Joshi,Vijay Kunadian,Bernard Prendergast,Nicholas L Mills,Vassilios S Vassiliou,Jason N Dungu,Sandeep S Hothi,Nicholas Boon,Sanjay K Prasad,Niall G Keenan,Dana Dawson,Manish Motwani,Christopher A Miller,Ronak Rajani,David P Ripley,Thomas A Treibel,Gerry P McCann,Anvesha Singh,David E Newby,Marc R Dweck, ","doi":"10.1001/jamacardio.2026.0654","DOIUrl":"https://doi.org/10.1001/jamacardio.2026.0654","url":null,"abstract":"ImportanceMyocardial fibrosis burden has been associated with adverse clinical outcomes in symptomatic patients with aortic stenosis.ObjectiveTo determine whether midwall myocardial fibrosis burden is associated with adverse clinical outcomes in asymptomatic patients and whether those with more fibrosis derive greater benefit from early intervention.Design, Setting, and ParticipantsThis post hoc analysis of a randomized clinical trial was conducted between August 2017 and October 2022. The trial took place at 24 cardiac centers across the United Kingdom and Australia. Participants included asymptomatic patients with severe aortic stenosis and midwall fibrosis on cardiac magnetic resonance. These data were analyzed from October 2024 through June 2025.InterventionEarly intervention with transcatheter or surgical aortic valve replacement.Main Outcomes and MeasuresPrimary outcome was all-cause death or unplanned aortic stenosis-related hospitalization. Secondary outcomes included the individual components of the primary outcome.ResultsIn 224 trial participants (mean [SD] age, 73 [9] years; 63 women and 161 men, and mean [SD] aortic valve peak velocity 4.3 [0.5] m per second) with a median follow-up of 42 months, fibrosis burden (per 1% increase) was associated with an increase in the primary end point (hazard ratio [HR], 1.23; 95% CI, 1.08-1.37) and its component of unplanned aortic stenosis-related hospitalizations (HR, 1.22; 95% CI, 1.03-1.40) but not all-cause death (HR, 1.17; 95% CI, 0.98-1.35). There were no interactions between randomization arm and the midwall fibrosis burden for the primary (P for interaction = .39) or secondary end points. In patients with high fibrosis burden above the median, the primary end point occurred in 12 of 59 (20%) of those randomized to early intervention and 17 of 53 (32%) of those randomized to guideline-directed conservative management (HR, 0.62; 95% CI, 0.29-1.28). For the individual components, all-cause death occurred in 9 (15%) and 10 (19%) patients, respectively (HR, 0.84; 95% CI, 0.33-2.07), and unplanned aortic stenosis-related hospitalization in 4 (7%) and 13 (25%) patients respectively (HR, 0.27; 95% CI, 0.08-0.77). In patients with low fibrosis burden below the median, there were no differences in the primary outcome (HR, 1.05; 95% CI, 0.39-2.86) or its components between intervention groups.Conclusions and RelevanceIn this study, in asymptomatic patients with severe aortic stenosis, higher midwall fibrosis burden was associated with adverse outcomes. There was no demonstrable heterogeneity by the degree of midwall fibrosis for the treatment effects of early surgical or transcatheter aortic valve replacement compared to clinical surveillance.Trial RegistrationClinicalTrials.gov Identifier: NCT03094143.","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"105 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147680663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Fibrosis-An Emerging Diagnostic and Therapeutic Target.","authors":"Peter S Natov,James E Udelson","doi":"10.1001/jamacardio.2026.0638","DOIUrl":"https://doi.org/10.1001/jamacardio.2026.0638","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"21 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147680664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial Fibroblast Activation in Ischemic and Nonischemic Cardiomyopathy.","authors":"Shruti S Joshi,Anna K Barton,Krithika Loganath,Neil J Craig,Menaka Mahendran,Beth Whittington,Tariq Ramtoola,Michelle C Williams,Edwin J R van Beek,Andrew H Baker,Alison Fletcher,Tim Clark,Clint Waight,Damini Dey,Piotr Slomka,David E Newby,Marc R Dweck","doi":"10.1001/jamacardio.2026.0661","DOIUrl":"https://doi.org/10.1001/jamacardio.2026.0661","url":null,"abstract":"ImportanceAdverse myocardial remodeling and fibrosis contribute to heart failure progression and are thought to be driven by activated fibroblasts. Noninvasive assessment of myocardial fibroblast activation may improve phenotyping and risk stratification in heart failure.ObjectiveTo evaluate myocardial fibroblast activation in patients with heart failure with reduced ejection fraction using gallium 68-labeled fibroblast activation protein inhibitor 46 ([68Ga]FAPI-46) positron emission tomography (PET) and magnetic resonance imaging (MRI).Design, Setting, and ParticipantsThis was a prospective case-control study including patients with heart failure with reduced ejection fraction, patients with prior myocardial infarction without heart failure, and healthy volunteers. A subset of patients with heart failure underwent repeat imaging after more than 6 months. Data analysis was conducted from January 2024 to January 2025.ExposureAll participants underwent [68Ga]FAPI-46 PET/MRI.Main Outcomes and MeasuresMyocardial fibroblast activation quantified using maximum standardized uptake values (SUVmax) of [68Ga]FAPI-46.ResultsA total of 81 participants were included (mean [SD] age, 66.2 [9.7] years; 22 [27%] female): 42 with heart failure (21 with heart failure due to ischemic cardiomyopathy from a previous myocardial infarction and 21 with a nonischemic etiology; mean [SD] left ventricular ejection fraction, 41% [9%]), 20 with a prior myocardial infarction but preserved left ventricular systolic function, and 19 healthy volunteers. No myocardial fibroblast activation was observed in healthy volunteers. All patients with heart failure demonstrated increased myocardial [68Ga]FAPI-46 uptake compared with healthy volunteers (mean [SD] SUVmax, 2.7 [1.5] vs 1.5 [0.3]; P &lt; .001). Uptake was highest in patients with ischemic cardiomyopathy, localizing to regions of established myocardial infarction (mean [SD] SUVmax, 3.2 [1.1]). Patients with nonischemic cardiomyopathy exhibited a different pattern of diffuse, lower-intensity uptake (mean [SD] SUVmax, 2.3 [0.5]), with the highest signal in the basal septum irrespective of late gadolinium enhancement. Patients with ischemic cardiomyopathy had higher uptake than patients with prior myocardial infarction without heart failure (n = 20) despite no major difference in infarct size (mean [SD] SUVmax, 3.2 [1.1] vs 2.5 [0.3]; P = .03). Among patients with heart failure who underwent repeat imaging, higher baseline [68Ga]FAPI-46 uptake was associated with less improvement in ejection fraction with optimal medical therapy over time (r = -0.52; P = .02).Conclusions and RelevanceIn this case-control study, patients with heart failure demonstrated persistent myocardial fibroblast activation with distinct spatial patterns according to cardiomyopathy etiology. Noninvasive imaging of fibroblast activation may provide mechanistic insights, aid risk stratification, and support the development of targeted antifibrotic therapies in hea","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"10 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147680358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial.","authors":"Ambarish Pandey,Neil Keshvani,Juan D Coellar,Anand K Jain,Matthew W Segar,Myriam Bustillo-Rubio,Syed K Rizvi,Eric D Peterson","doi":"10.1001/jamacardio.2026.0435","DOIUrl":"https://doi.org/10.1001/jamacardio.2026.0435","url":null,"abstract":"ImportanceLow-quality dietary intake is associated with adverse heart failure (HF) outcomes, yet evidence evaluating food-as-medicine interventions that supply high-quality dietary content is limited.ObjectiveTo determine the feasibility of providing food supplementation with medically tailored meals or fresh produce and explore the association of food supplementation vs usual care with clinical outcomes in patients recently hospitalized with HF and whether it differs by conditioning food supplementation to health care engagement.Design, Setting, and ParticipantsThis open-label factorial randomized clinical trial was conducted between April 2024 and October 2025 at 2 hospitals in Dallas, Texas. The study included patients who were hospitalized for HF and enrolled within 14 days of discharge, excluding those with prior heart transplant, a left ventricular assist device, or inotropic support at discharge; current enrollment in meal delivery programs; and inability to receive home deliveries. Participants were followed up with for 12 weeks. Of 150 participants enrolled, 2 were withdrawn due to clinical deterioration, 1 died, and 6 were lost to follow-up; all were included in the intention-to-treat analysis.InterventionsParticipants were randomized 1:1:1 to medically tailored meals, fresh produce, or usual care. Those receiving food supplementation underwent secondary 1:1 randomization to conditional (linked to clinic attendance and medication fills) vs unconditional delivery.Main Outcomes and MeasuresImplementation outcomes included delivery completion, adherence, and acceptability and exploratory clinical outcomes. The primary clinical outcome was defined as readmission for HF or emergency department (ED) visits for HF over 90-day follow-up. Secondary clinical outcomes included a win-ratio-based hierarchical composite (all-cause death, total HF hospitalizations or ED visits, and ≥10-point Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score [KCCQ-CSS] improvement).ResultsAmong 150 participants (median [IQR] age, 59.5 [52.0-66.0] years; 91 [60.7%] male), the baseline median (IQR) left ventricular ejection fraction was 35% (25.0-54.0), the baseline median (IQR) KCCQ-CSS was 56.6 (36.8-72.9), and 79 (52.7%) had food insecurity. Food delivery completion was 93.6% with a mean (SD) reported consumption adherence of 4.7 (2.4) days per week (medically tailored meals) and 5.5 (2.3) days per week (fresh produce), with high retention (96.0%). Fresh produce demonstrated superior acceptability compared with medically tailored meals (Net Promoter Score: 8.6 vs 7.3; P = .02). There was no significant difference in the primary clinical outcome (HF readmission or ED visit) between food supplementation (23 events among 100 participants) vs usual care (9 events among 50 participants) (adjusted rate ratio, 1.09; 95% CI, 0.49-2.43; P = .83). The hierarchical composite favored food supplementation vs usual care (win ratio, 1.21; 95% CI, 1.14-1.29; P &lt; .001). ","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"22 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147630187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia.","authors":"Borna Naderi,Christopher O Y Li,Brianna Davies,Dania Kallas,Zachary W M Laksman,Sonia Franciosi,Shubhayan Sanatani,Andrew D Krahn,Thomas M Roston","doi":"10.1001/jamacardio.2026.0384","DOIUrl":"https://doi.org/10.1001/jamacardio.2026.0384","url":null,"abstract":"ImportanceCatecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inherited arrhythmogenic syndrome in which exercise stress testing is the primary method for provoking adrenergically mediated ventricular arrhythmias. Traditional exercise testing protocols, such as the Bruce protocol, may lack sensitivity, leading to missed diagnoses and undertreatment, whereas early pilot data suggest that a sudden high-intensity Burst protocol may better unmask arrhythmias.ObjectiveTo evaluate the diagnostic yield and therapeutic impact of the Burst exercise stress testing protocol compared with the traditional Bruce protocol in CPVT.Design, Setting, and ParticipantsThis retrospective cohort study included pediatric and adult patients evaluated for CPVT at 2 tertiary referral centers in Vancouver, British Columbia, Canada. Data were collected from May 2017 through May 2024, and data analysis was performed from May 2024 through April 2025. Of 38 screened patients, 28 were included who had undergone consecutive Bruce and Burst exercise tests, with available tracings and a diagnostic phenotype on at least 1 test. Arrhythmia severity was scored using the Ventricular Arrhythmia Score.ExposureType of exercise stress testing protocol (Bruce vs Burst).Main Outcomes and MeasuresThe main outcome was the Ventricular Arrhythmia Score (ranging from 0 = no premature ventricular contractions to 4 = nonsustained ventricular tachycardia). Other outcomes included changes in pharmacologic therapy and adverse events.ResultsThe cohort included 13 female patients (46%) and 18 probands (64%), including 23 (82%) with a causative RYR2 variant. Median (IQR) age at testing was 19.9 (14.8-33.9) years for Bruce testing and 21.0 (16.1-35.5) years at Burst testing. Bruce and Burst exercise tests were performed a median (IQR) of 1.3 (0.6-2.0) years apart, with all Burst tests performed on equivalent or intensified therapy. The Burst protocol provoked more severe arrhythmias in 20 of 28 patients (71%) with a higher median (IQR) Ventricular Arrhythmia Score (3 [2-4] vs 1 [1-2]; P < .001). These findings prompted β-blocker or flecainide initiation or dose escalation in 13 patients (65%). No adverse safety events occurred.Conclusions and RelevanceIn this cohort study, the Burst exercise stress testing protocol detected a greater burden and severity of ventricular arrhythmias than the Bruce protocol in patients with CPVT, frequently prompting treatment escalation without observed safety concerns. These data suggest that incorporating Burst protocol exercise stress testing into the routine care of patients with CPVT is low risk and often informative.","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"9 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147630186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}